Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.43 |
| ▸ | CMA1 | P23946 | 6/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24414109 | 0.88 | KMT2A (0.48) | CASP3F2KMT2A | |
| SCHEMBL30517416 | 0.86 | ITGB3 (0.43) | CASP3F2MDM4TP53KMT2A | |
| SCHEMBL24414250 | 0.84 | ELANE (0.37) | CASP3CMA1F2KMT2AELANE | |
| SCHEMBL30429508 | 0.81 | OPRM1 (0.48) | CMA1 | |
| SCHEMBL24414218 | 0.80 | MDM4 (0.32) | CASP3CMA1F2MDM4TP53 | |
| SCHEMBL30116837 | 0.77 | F2 (0.45) | F2TP53KMT2A | |
| SCHEMBL8923645 | 0.76 | CMA1 (0.47) | CMA1ELANE | |
| SCHEMBL29413336 | 0.76 | CTRB1 (0.49) | F2KMT2A | |
| SCHEMBL30317756 | 0.76 | CTRB1 (0.49) | F2KMT2A | |
| SCHEMBL8902510 | 0.76 | CTRB1 (0.49) | F2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023214577-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | 中外製薬株式会社 | 2023-11-09 | — | — | WO | disclosed |
| WO-2022097540-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | 中外製薬株式会社 | 2022-05-12 | — | — | WO | disclosed |